Achieve Life Sciences, Inc. (ACHV)
USD 2.57
(4.9%)
USD 2.57
(4.9%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -27.25 Million USD | 33.21% |
| 2022 | -40.8 Million USD | -23.29% |
| 2021 | -33.09 Million USD | -124.37% |
| 2020 | -14.75 Million USD | 10.76% |
| 2019 | -16.52 Million USD | -28.99% |
| 2018 | -12.81 Million USD | -93.2% |
| 2017 | -6.63 Million USD | 68.71% |
| 2016 | -21.19 Million USD | -13.01% |
| 2015 | -18.75 Million USD | 36.36% |
| 2014 | -29.46 Million USD | 16.59% |
| 2013 | -35.32 Million USD | -35.94% |
| 2012 | -25.98 Million USD | -16.6% |
| 2011 | -22.28 Million USD | -51.15% |
| 2010 | -14.74 Million USD | -498.17% |
| 2009 | -2.46 Million USD | 60.64% |
| 2008 | -6.26 Million USD | 58.89% |
| 2007 | -15.23 Million USD | 42.04% |
| 2006 | -26.28 Million USD | -20.53% |
| 2005 | -21.8 Million USD | -31.57% |
| 2004 | -16.57 Million USD | -55.81% |
| 2003 | -10.63 Million USD | 12.62% |
| 2002 | -12.17 Million USD | -5727.12% |
| 2001 | 216.34 Thousand USD | 102.99% |
| 2000 | -7.23 Million USD | -903.64% |
| 1999 | 900 Thousand USD | 107.56% |
| 1998 | -11.9 Million USD | -12000.0% |
| 1997 | 100 Thousand USD | -93.75% |
| 1996 | 1.6 Million USD | 132.0% |
| 1995 | -5 Million USD | 39.02% |
| 1994 | -8.2 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -8.46 Million USD | -41.44% |
| 2024 Q1 | -5.98 Million USD | -36.39% |
| 2023 Q3 | -6.57 Million USD | 14.8% |
| 2023 FY | -27.25 Million USD | 33.21% |
| 2023 Q2 | -7.71 Million USD | 8.37% |
| 2023 Q1 | -8.41 Million USD | 22.49% |
| 2023 Q4 | -4.38 Million USD | 33.26% |
| 2022 Q3 | -12.59 Million USD | -25.16% |
| 2022 FY | -40.8 Million USD | -23.29% |
| 2022 Q4 | -10.86 Million USD | 13.77% |
| 2022 Q1 | -7.22 Million USD | -1.56% |
| 2022 Q2 | -10.06 Million USD | -39.27% |
| 2021 Q3 | -6.69 Million USD | 40.85% |
| 2021 FY | -33.09 Million USD | -124.37% |
| 2021 Q4 | -7.11 Million USD | -6.34% |
| 2021 Q1 | -7.98 Million USD | -69.01% |
| 2021 Q2 | -11.31 Million USD | -41.67% |
| 2020 FY | -14.75 Million USD | 10.76% |
| 2020 Q1 | -3.32 Million USD | -3.46% |
| 2020 Q2 | -2.92 Million USD | 11.99% |
| 2020 Q3 | -3.75 Million USD | -28.47% |
| 2020 Q4 | -4.72 Million USD | -25.84% |
| 2019 Q3 | -3.67 Million USD | -1.35% |
| 2019 Q2 | -3.62 Million USD | 38.62% |
| 2019 Q1 | -5.9 Million USD | -59.18% |
| 2019 Q4 | -3.2 Million USD | 12.63% |
| 2019 FY | -16.52 Million USD | -28.99% |
| 2018 Q2 | -2.78 Million USD | 7.74% |
| 2018 Q1 | -3.02 Million USD | 20.1% |
| 2018 Q3 | -3.24 Million USD | -16.21% |
| 2018 Q4 | -3.7 Million USD | -14.48% |
| 2018 FY | -12.81 Million USD | -93.2% |
| 2017 FY | -6.63 Million USD | 68.71% |
| 2017 Q4 | -3.78 Million USD | -59.24% |
| 2017 Q3 | -2.37 Million USD | 23.11% |
| 2017 Q2 | -3.08 Million USD | 7.68% |
| 2017 Q1 | -3.34 Million USD | 44.35% |
| 2016 Q4 | -6.01 Million USD | -37.75% |
| 2016 Q2 | -6.38 Million USD | -44.0% |
| 2016 Q3 | -4.36 Million USD | 31.6% |
| 2016 FY | -21.19 Million USD | -13.01% |
| 2016 Q1 | -4.43 Million USD | -27.43% |
| 2015 Q4 | -3.47 Million USD | 25.86% |
| 2015 Q1 | -4.99 Million USD | 25.03% |
| 2015 FY | -18.75 Million USD | 36.36% |
| 2015 Q2 | -5.58 Million USD | -11.81% |
| 2015 Q3 | -4.69 Million USD | 16.04% |
| 2014 FY | -29.46 Million USD | 16.59% |
| 2014 Q4 | -6.66 Million USD | -35.83% |
| 2014 Q2 | -7.63 Million USD | 3.77% |
| 2014 Q1 | -7.92 Million USD | -12.68% |
| 2014 Q3 | -4.9 Million USD | 35.69% |
| 2013 Q1 | -8.27 Million USD | -101.78% |
| 2013 FY | -35.32 Million USD | -35.94% |
| 2013 Q4 | -7.03 Million USD | 33.71% |
| 2013 Q3 | -10.61 Million USD | -12.97% |
| 2013 Q2 | -9.39 Million USD | -13.49% |
| 2012 Q1 | -5.5 Million USD | 30.97% |
| 2012 FY | -25.98 Million USD | -16.6% |
| 2012 Q2 | -5.94 Million USD | -8.01% |
| 2012 Q3 | -8.29 Million USD | -39.47% |
| 2012 Q4 | -4.1 Million USD | 50.51% |
| 2011 Q3 | -4.09 Million USD | 17.95% |
| 2011 FY | -22.28 Million USD | -51.15% |
| 2011 Q4 | -7.97 Million USD | -94.58% |
| 2011 Q2 | -4.99 Million USD | 4.44% |
| 2011 Q1 | -5.22 Million USD | -172.85% |
| 2010 Q2 | -2.84 Million USD | 6.07% |
| 2010 FY | -14.74 Million USD | -498.17% |
| 2010 Q4 | -1.91 Million USD | 72.43% |
| 2010 Q1 | -3.03 Million USD | -144.04% |
| 2010 Q3 | -6.94 Million USD | -144.1% |
| 2009 Q2 | -4.55 Million USD | -88.38% |
| 2009 Q4 | 6.88 Million USD | 390.42% |
| 2009 FY | -2.46 Million USD | 60.64% |
| 2009 Q1 | -2.41 Million USD | 50.78% |
| 2009 Q3 | -2.36 Million USD | 48.01% |
| 2008 FY | -6.26 Million USD | 58.89% |
| 2008 Q2 | -3.99 Million USD | 8.59% |
| 2008 Q4 | -4.91 Million USD | -84.57% |
| 2008 Q3 | -2.66 Million USD | 33.34% |
| 2008 Q1 | -4.37 Million USD | -384.51% |
| 2007 FY | -15.23 Million USD | 42.04% |
| 2007 Q3 | -6.35 Million USD | 3.05% |
| 2007 Q2 | -6.55 Million USD | -69.6% |
| 2007 Q1 | -3.86 Million USD | 49.84% |
| 2007 Q4 | 1.53 Million USD | 124.18% |
| 2006 FY | -26.28 Million USD | -20.53% |
| 2006 Q3 | -7.13 Million USD | -26.92% |
| 2006 Q2 | -5.62 Million USD | 3.48% |
| 2006 Q1 | -5.82 Million USD | -55.92% |
| 2006 Q4 | -7.7 Million USD | -7.94% |
| 2005 Q3 | -9.04 Million USD | -117.12% |
| 2005 Q1 | -4.86 Million USD | 10.75% |
| 2005 FY | -21.8 Million USD | -31.57% |
| 2005 Q2 | -4.16 Million USD | 14.42% |
| 2005 Q4 | -3.73 Million USD | 58.68% |
| 2004 Q2 | -3.81 Million USD | -5.61% |
| 2004 Q4 | -5.45 Million USD | -47.67% |
| 2004 Q3 | -3.69 Million USD | 3.27% |
| 2004 Q1 | -3.61 Million USD | -36.52% |
| 2004 FY | -16.57 Million USD | -55.81% |
| 2003 Q4 | -2.64 Million USD | -4.21% |
| 2003 Q2 | -3.11 Million USD | -33.52% |
| 2003 Q3 | -2.54 Million USD | 18.48% |
| 2003 FY | -10.63 Million USD | 12.62% |
| 2003 Q1 | -2.33 Million USD | 9.71% |
| 2002 Q4 | -2.58 Million USD | 23.37% |
| 2002 Q1 | -2.52 Million USD | -12.63% |
| 2002 Q3 | -3.37 Million USD | 8.67% |
| 2002 FY | -12.17 Million USD | -5727.12% |
| 2002 Q2 | -3.69 Million USD | -46.49% |
| 2001 Q1 | -627.36 Thousand USD | -1367.38% |
| 2001 FY | 216.34 Thousand USD | 102.99% |
| 2001 Q4 | -2.23 Million USD | -144.12% |
| 2001 Q3 | 5.07 Million USD | 374.31% |
| 2001 Q2 | -1.84 Million USD | -194.85% |
| 2000 Q2 | -2.37 Million USD | 3.9% |
| 2000 Q4 | -42.75 Thousand USD | 98.17% |
| 2000 Q3 | -2.33 Million USD | 1.86% |
| 2000 FY | -7.23 Million USD | -903.64% |
| 2000 Q1 | -2.47 Million USD | -40.67% |
| 1999 Q2 | -3.2 Million USD | -113.33% |
| 1999 Q4 | -1.76 Million USD | -192.63% |
| 1999 FY | 900 Thousand USD | 107.56% |
| 1999 Q1 | -1.5 Million USD | 48.28% |
| 1999 Q3 | 1.9 Million USD | 159.38% |
| 1998 Q4 | -2.9 Million USD | -31.82% |
| 1998 FY | -11.9 Million USD | -12000.0% |
| 1998 Q3 | -2.2 Million USD | 33.33% |
| 1998 Q2 | -3.3 Million USD | 8.33% |
| 1998 Q1 | -3.6 Million USD | -805.88% |
| 1997 Q1 | 1.3 Million USD | -48.0% |
| 1997 Q2 | 200 Thousand USD | -84.62% |
| 1997 FY | 100 Thousand USD | -93.75% |
| 1997 Q3 | -1.4 Million USD | -800.0% |
| 1997 Q4 | 510 Thousand USD | 136.43% |
| 1996 FY | 1.6 Million USD | 132.0% |
| 1996 Q1 | -4.7 Million USD | -46.88% |
| 1996 Q2 | 900 Thousand USD | 119.15% |
| 1996 Q3 | 3 Million USD | 233.33% |
| 1996 Q4 | 2.5 Million USD | -16.67% |
| 1995 Q4 | -3.2 Million USD | -100.0% |
| 1995 Q3 | -1.6 Million USD | -184.21% |
| 1995 Q2 | 1.9 Million USD | 5.56% |
| 1995 Q1 | 1.8 Million USD | 120.69% |
| 1995 FY | -5 Million USD | 39.02% |
| 1994 Q2 | 100 Thousand USD | 0.0% |
| 1994 Q1 | 100 Thousand USD | 0.0% |
| 1994 Q4 | -8.7 Million USD | -1840.0% |
| 1994 FY | -8.2 Million USD | 0.0% |
| 1994 Q3 | 500 Thousand USD | 400.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Absci Corporation | -115.51 Million USD | 76.41% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 87.997% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 90.343% |
| Alzamend Neuro, Inc. | -9.93 Million USD | -174.21% |
| Apollomics, Inc. | -54.83 Million USD | 50.305% |
| 180 Life Sciences Corp. | -13.47 Million USD | -102.189% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 13.153% |
| Bicycle Therapeutics plc | -189.94 Million USD | 85.654% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 67.526% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 84.137% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | -7.793% |
| Chimerix, Inc. | -93.06 Million USD | 70.719% |
| CRISPR Therapeutics AG | -222.53 Million USD | 87.755% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | 269.497% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 63.007% |
| Fortress Biotech, Inc. | -142.34 Million USD | 80.856% |
| Fortress Biotech, Inc. | -142.34 Million USD | 80.856% |
| Gritstone bio, Inc. | -154.63 Million USD | 82.378% |
| Allakos Inc. | -196.05 Million USD | 86.101% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 50.27% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 77.571% |
| Cytokinetics, Incorporated | -496.2 Million USD | 94.508% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | -4.566% |
| Innoviva, Inc. | 176.7 Million USD | 115.421% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | -254.253% |
| NLS Pharmaceutics AG | -11.8 Million USD | -130.794% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 78.554% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | -211223.201% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 73.43% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 69.336% |
| ImmuCell Corporation | -5.74 Million USD | -374.072% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 79.729% |
| Incyte Corporation | 620.52 Million USD | 104.391% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 79.849% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -317.048% |
| Mustang Bio, Inc. | -50.72 Million USD | 46.28% |
| MiMedx Group, Inc. | 37.11 Million USD | 173.418% |
| MEI Pharma, Inc. | 14.54 Million USD | 287.388% |
| MacroGenics, Inc. | -168.24 Million USD | 83.803% |
| Monopar Therapeutics Inc. | -8.83 Million USD | -208.564% |
| Mereo BioPharma Group plc | -28.41 Million USD | 4.103% |
| Marker Therapeutics, Inc. | -14.58 Million USD | -86.882% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 79.275% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 13.897% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | -17.865% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -71.535% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | -126.16% |
| NextCure, Inc. | -67.63 Million USD | 59.711% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 47.094% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | -157.976% |
| Onconetix, Inc. | -36.03 Million USD | 24.378% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 34.674% |
| Opthea Limited | -191.84 Million USD | 85.796% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 54.033% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -890.252% |
| PDS Biotechnology Corporation | -43.04 Million USD | 36.695% |
| Precigen, Inc. | -88.92 Million USD | 69.356% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 8.422% |
| Prime Medicine, Inc. | -191.29 Million USD | 85.755% |
| PureTech Health plc | -146.19 Million USD | 81.361% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 89.505% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 100.673% |
| Replimune Group, Inc. | -234.77 Million USD | 88.393% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -214.786% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | -32.985% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | -40.33% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 94.407% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -12.109% |
| Sesen Bio, Inc. | -25.9 Million USD | -5.176% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 90.055% |
| Solid Biosciences Inc. | -104.31 Million USD | 73.877% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 88.15% |
| SciSparc Ltd. | -5.77 Million USD | -372.025% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 69.477% |
| TG Therapeutics, Inc. | 20.63 Million USD | 232.07% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 76.981% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | -274.468% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 92.767% |
| UroGen Pharma Ltd. | -65.53 Million USD | 58.42% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 58.561% |
| XOMA Corporation | -41.84 Million USD | 34.883% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 89.056% |
| AbCellera Biologics Inc. | -237.2 Million USD | 88.512% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 51.99% |
| Cassava Sciences, Inc. | -105.95 Million USD | 74.282% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 39.548% |
| Precision BioSciences, Inc. | -43.73 Million USD | 37.694% |
| Dyadic International, Inc. | -8.22 Million USD | -231.116% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | -227.563% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | -2186.074% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 6.863% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 79.229% |
| IGM Biosciences, Inc. | -263.46 Million USD | 89.657% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 74.656% |
| Acelyrin, Inc. | -422.06 Million USD | 93.544% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 42.187% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | 328.186% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | -35.641% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 65.156% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 78.874% |
| Senti Biosciences, Inc. | -92.72 Million USD | 70.613% |
| Mesoblast Limited | -58.79 Million USD | 53.652% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 83.538% |
| ChromaDex Corporation | -5.59 Million USD | -386.694% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -468.719% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 41.089% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | -238.85% |
| Seer, Inc. | -103.46 Million USD | 73.662% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 38.082% |
| Novavax, Inc. | -566.51 Million USD | 95.19% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | -73.68% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 85.696% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 47.745% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 88.9% |
| Celcuity Inc. | -66.23 Million USD | 58.856% |
| ContextLogic Inc. | -328 Million USD | 91.692% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 83.713% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 72.107% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 104.71% |
| Amarin Corporation plc | -67.58 Million USD | 59.682% |
| AnaptysBio, Inc. | -164.41 Million USD | 83.426% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 5.638% |
| Aptorum Group Limited | -10.52 Million USD | -158.948% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 68.466% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 86.707% |
| Ardelyx, Inc. | -63.27 Million USD | 56.935% |
| Celularity Inc. | -192.28 Million USD | 85.828% |
| Omeros Corporation | -164.53 Million USD | 83.438% |
| Humacyte, Inc. | -100.04 Million USD | 72.763% |
| Immunocore Holdings plc | -59.64 Million USD | 54.316% |
| IO Biotech, Inc. | -91.44 Million USD | 70.2% |
| GT Biopharma, Inc. | -13.57 Million USD | -100.722% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 63.501% |
| Summit Therapeutics Inc. | -89.73 Million USD | 69.633% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 20.477% |
| Pulmatrix, Inc. | -14.74 Million USD | -84.871% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 94.712% |
| Evogene Ltd. | -26.39 Million USD | -3.255% |
| CorMedix Inc. | -48.95 Million USD | 44.34% |
| BioLineRx Ltd. | -49.69 Million USD | 45.164% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 17.477% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 11.353% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 92.201% |
| scPharmaceuticals Inc. | -55.39 Million USD | 50.809% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 75.376% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 125.4% |
| NLS Pharmaceutics AG | -11.8 Million USD | -130.794% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | -12.109% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 84.237% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | -26.945% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | -5.998% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 76.257% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 67.19% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 48.707% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | -44.197% |
| Daré Bioscience, Inc. | -30.83 Million USD | 11.64% |
| bluebird bio, Inc. | -244.26 Million USD | 88.844% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 114.015% |
| DBV Technologies S.A. | -76.43 Million USD | 64.347% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 88.434% |
| Galecto, Inc. | -39.9 Million USD | 31.713% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 26.479% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 47.589% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 87.57% |
| GlycoMimetics, Inc. | -39.27 Million USD | 30.618% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 88.698% |
| ADMA Biologics, Inc. | 21.63 Million USD | 225.971% |
| Clene Inc. | -40.54 Million USD | 32.782% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 92.216% |
| Aptose Biosciences Inc. | -52.35 Million USD | 47.952% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | -88.964% |
| Soligenix, Inc. | -7.69 Million USD | -253.991% |
| Century Therapeutics, Inc. | -146.54 Million USD | 81.405% |
| Kura Oncology, Inc. | -165.8 Million USD | 83.565% |
| Surrozen, Inc. | -45.78 Million USD | 40.476% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 70.843% |
| Ocean Biomedical, Inc. | -2.48 Million USD | -998.065% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | -320.265% |
| Autolus Therapeutics plc | -195.02 Million USD | 86.028% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 67.811% |
| Eterna Therapeutics Inc. | -21.13 Million USD | -28.933% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 76.521% |
| GRI Bio, Inc. | -11.38 Million USD | -139.308% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -503.448% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 62.66% |
| INmune Bio, Inc. | -29.74 Million USD | 8.376% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 75.365% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 28.431% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -70.532% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | -230.947% |
| Jaguar Health, Inc. | -34.29 Million USD | 20.533% |
| Entero Therapeutics, Inc. | -15.77 Million USD | -72.787% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 55.4% |
| Clearside Biomedical, Inc. | -24.84 Million USD | -9.684% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 90.127% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 86.59% |
| Verastem, Inc. | -92.08 Million USD | 70.407% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 85.202% |
| Histogen Inc. | -10.64 Million USD | -156.037% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | -76.125% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 62.864% |
| Surrozen, Inc. | -45.78 Million USD | 40.476% |
| Organovo Holdings, Inc. | -15.08 Million USD | -80.631% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -435.339% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | -257.01% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 84.091% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 43.754% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | -79.032% |
| Kronos Bio, Inc. | -121.83 Million USD | 77.633% |
| Turnstone Biologics Corp. | -59.03 Million USD | 53.839% |
| Synaptogenix, Inc. | -8.31 Million USD | -227.766% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | -86.823% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | -761.796% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 70.281% |
| Exelixis, Inc. | 170.88 Million USD | 115.946% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 82.426% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 94.73% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 60.428% |
| ESSA Pharma Inc. | -32.13 Million USD | 15.199% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | -59.142% |
| Avid Bioservices, Inc. | -18.67 Million USD | -45.894% |
| Insmed Incorporated | -709.62 Million USD | 96.16% |
| MediWound Ltd. | -15.29 Million USD | -78.221% |
| OmniAb, Inc. | -69.41 Million USD | 60.746% |
| Alector, Inc. | -151.74 Million USD | 82.042% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 74.765% |
| Zai Lab Limited | -366.57 Million USD | 92.566% |
| AlloVir, Inc. | -181.33 Million USD | 84.972% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 91.398% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 75.402% |
| Aura Biosciences, Inc. | -84.99 Million USD | 67.938% |
| Immunic, Inc. | -99.22 Million USD | 72.537% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 80.965% |
| Veracyte, Inc. | -85.79 Million USD | 68.238% |
| InMed Pharmaceuticals Inc. | - USD | Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 90.331% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -91.766% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 131.39% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | -295.619% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | -45.004% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | -7.06% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 170.228% |
| Fortrea Holdings Inc. | 63.1 Million USD | 143.185% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 80.597% |
| XBiotech Inc. | -37.51 Million USD | 27.353% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 60.428% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 83.965% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 28.041% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 59.401% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 74.747% |
| Agenus Inc. | -159.54 Million USD | 82.921% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -6.147% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 48.867% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 95.213% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 65.283% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 73.725% |
| Gain Therapeutics, Inc. | -22.25 Million USD | -22.455% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 80.4% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | -384.864% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | -7.035% |
| Lantern Pharma Inc. | -17.87 Million USD | -52.426% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 36.628% |
| Ainos, Inc. | -13.2 Million USD | -106.339% |
| Pluri Inc. | -22.15 Million USD | -22.98% |
| Prothena Corporation plc | -191.03 Million USD | 85.736% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 80.259% |
| Rallybio Corporation | -78.93 Million USD | 65.477% |
| Kodiak Sciences Inc. | -277.32 Million USD | 90.174% |
| Cue Biopharma, Inc. | -52.14 Million USD | 47.746% |
| MeiraGTx Holdings plc | -137.06 Million USD | 80.118% |
| Annexon, Inc. | -143.72 Million USD | 81.04% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 57.847% |
| Moderna, Inc. | -4.23 Billion USD | 99.357% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | -46.829% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | -11.302% |
| Blueprint Medicines Corporation | -486.27 Million USD | 94.396% |
| Immix Biopharma, Inc. | -16.14 Million USD | -68.824% |
| CalciMedica, Inc. | -21.87 Million USD | -24.571% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 80.985% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 84.092% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 59.924% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 91.664% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 23.766% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 59.66% |
| Nutriband Inc. | -4.87 Million USD | -459.327% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 37.519% |
| Vor Biopharma Inc. | -126.03 Million USD | 78.379% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 100.642% |
| Alkermes plc | 414.12 Million USD | 106.58% |
| ProKidney Corp. | -151.52 Million USD | 82.016% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 57.775% |
| Arcellx, Inc. | -89.88 Million USD | 69.682% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 95.513% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 76.133% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 28.425% |
| Atai Life Sciences N.V. | -125.47 Million USD | 78.282% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 66.621% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 66.527% |
| MediciNova, Inc. | -9.9 Million USD | -175.245% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 78.437% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -276.253% |
| GeoVax Labs, Inc. | -26.74 Million USD | -1.896% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 88.245% |
| Biomea Fusion, Inc. | -126.13 Million USD | 78.396% |
| RenovoRx, Inc. | -11.39 Million USD | -139.119% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 85.74% |
| Geron Corporation | -193.94 Million USD | 85.95% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 1.222% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 75.857% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 88.747% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | -8.152% |
| Royalty Pharma plc | 1.49 Billion USD | 101.826% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 86.899% |
| Imunon, Inc. | -21.03 Million USD | -29.574% |
| BioAtla, Inc. | -129.68 Million USD | 78.988% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 91.685% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 34.743% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 84.06% |
| Structure Therapeutics Inc. | -102.77 Million USD | 73.486% |
| 89bio, Inc. | -151.2 Million USD | 81.978% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 74.106% |
| aTyr Pharma, Inc. | -54.91 Million USD | 50.381% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 68.831% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 89.291% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | -231.801% |
| Akari Therapeutics, Plc | -16.8 Million USD | -62.144% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -308052.296% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 108.072% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 84.134% |
| Liquidia Corporation | -73.38 Million USD | 62.867% |
| Entera Bio Ltd. | -8.89 Million USD | -206.49% |
| GH Research PLC | -41.22 Million USD | 33.895% |
| Vericel Corporation | -6.46 Million USD | -321.566% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 65.11% |
| Xencor, Inc. | -138.63 Million USD | 80.345% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | -428.656% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | -70.532% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | -26.797% |
| Vaxcyte, Inc. | -468.04 Million USD | 94.178% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 87.27% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | -95.313% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -317.048% |
| Portage Biotech Inc. | -18.25 Million USD | -49.291% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -276.253% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 74.038% |
| OncoCyte Corporation | -25.13 Million USD | -8.41% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -141.047% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -137.845% |
| Purple Biotech Ltd. | 22.27 Million USD | 222.356% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 6.54% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 7.012% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 85.219% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | -262.753% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 8.036% |
| United Therapeutics Corporation | 1.18 Billion USD | 102.3% |
| HilleVax, Inc. | -133.34 Million USD | 79.564% |
| Silo Pharma, Inc. | -3.85 Million USD | -606.766% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | -591.265% |
| Pharming Group N.V. | -4.87 Million USD | -458.454% |
| Tharimmune, Inc. | -9.45 Million USD | -188.201% |
| Genprex, Inc. | -31.07 Million USD | 12.311% |
| Apogee Therapeutics, Inc. | -93 Million USD | 70.7% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 85.52% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 66.848% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | -3462.092% |
| Virios Therapeutics, Inc. | -5.44 Million USD | -400.283% |
| OKYO Pharma Limited | -15.74 Thousand USD | -172918.839% |
| Savara Inc. | -60 Million USD | 54.589% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -55.368% |
| Curis, Inc. | -48.33 Million USD | 43.619% |
| Carmell Therapeutics Corporation | -5.21 Million USD | -422.303% |
| BeiGene, Ltd. | -1.2 Billion USD | 97.744% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 70.903% |
| Erasca, Inc. | -141.52 Million USD | 80.745% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -501.947% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -501.947% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 36.046% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | -328.459% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 59.472% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 82.367% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 86.907% |
| Adicet Bio, Inc. | -152.03 Million USD | 82.077% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 62.922% |
| Aditxt, Inc. | -26.06 Million USD | -4.557% |
| Adagene Inc. | -23.71 Million USD | -14.883% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -272.772% |
| Quantum-Si incorporated | -111.17 Million USD | 75.488% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | -86.928% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 122.334% |
| Compugen Ltd. | -12.99 Million USD | -109.744% |
| Generation Bio Co. | -138.56 Million USD | 80.334% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 67.181% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 68.483% |
| Invivyd, Inc. | -207.78 Million USD | 86.885% |
| Relay Therapeutics, Inc. | -373 Million USD | 92.694% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | -190.558% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 226.856% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -164.897% |
| 2seventy bio, Inc. | -216.7 Million USD | 87.425% |
| Instil Bio, Inc. | -159.16 Million USD | 82.88% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | -13.175% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | -642.695% |
| GeoVax Labs, Inc. | -26.74 Million USD | -1.896% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 25.814% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 73.723% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 83.997% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 96.018% |
| Evaxion Biotech A/S | -22.19 Million USD | -22.764% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 66.922% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 87.787% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 65.914% |
| Cingulate Inc. | -22.75 Million USD | -19.732% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | 463.721% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 38.993% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 56.101% |
| Clearmind Medicine Inc. | -8.74 Million USD | -211.737% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 64.237% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -829.088% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 72.974% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 92.838% |
| ImmunityBio, Inc. | -362.25 Million USD | 92.478% |
| Korro Bio, Inc. | -84.53 Million USD | 67.764% |
| Kineta, Inc. | -15.72 Million USD | -73.313% |
| BioVie Inc. | -32.17 Million USD | 15.319% |
| Codexis, Inc. | -68.06 Million USD | 59.967% |
| Celularity Inc. | -192.28 Million USD | 85.828% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | -67.424% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 87.759% |
| Virax Biolabs Group Limited | -6.49 Million USD | -319.458% |
| Cibus, Inc. | -318.88 Million USD | 91.455% |
| IN8bio, Inc. | -30.33 Million USD | 10.176% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 77.987% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | -16.234% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 92.296% |
| Eyenovia, Inc. | -25.4 Million USD | -7.256% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 183.487% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -389.932% |
| Elevation Oncology, Inc. | -45.44 Million USD | 40.037% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 65.564% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 39.994% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 80.139% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 12.405% |
| Moolec Science SA | -6.65 Million USD | -309.54% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 55.429% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 36.999% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 83.401% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 45.893% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -192.135% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | -24.46% |
| Humacyte, Inc. | -100.04 Million USD | 72.763% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 65.994% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | -87.414% |
| Genelux Corporation | -24.16 Million USD | -12.766% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 19.671% |
| Notable Labs, Ltd. | -14.65 Million USD | -85.918% |
| Immunovant, Inc. | -282.7 Million USD | 90.361% |
| Quantum-Si incorporated | -111.17 Million USD | 75.488% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | -28.133% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 73.287% |
| Acasti Pharma Inc. | -11.31 Million USD | -140.895% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | -18.886% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 34.153% |
| PepGen Inc. | -84.76 Million USD | 67.853% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -19.011% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 16.941% |
| Immuneering Corporation | -58.41 Million USD | 53.349% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -435.339% |
| Belite Bio, Inc | -31.66 Million USD | 13.951% |
| XOMA Corporation | -41.84 Million USD | 34.883% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 59.642% |
| Bionomics Limited | -17.89 Billion USD | 99.848% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 176.373% |
| uniQure N.V. | -282.87 Million USD | 90.367% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -272.772% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 78.958% |
| Forte Biosciences, Inc. | -32.48 Million USD | 16.118% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | -227.967% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 7.297% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -389.932% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | -91.766% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | -206.559% |
| Altimmune, Inc. | -95.92 Million USD | 71.594% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 62.727% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 176.373% |
| Peak Bio, Inc. | -1356.23 USD | -2009146.219% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 45.065% |
| Benitec Biopharma Inc. | -22.49 Million USD | -21.165% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 88.754% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 8.391% |
| Zura Bio Limited | -62.63 Million USD | 56.496% |
| PolyPid Ltd. | -22.86 Million USD | -19.167% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 8.391% |
| argenx SE | -425.04 Million USD | 93.589% |
| Immunome, Inc. | -109.53 Million USD | 75.121% |
| Verona Pharma plc | -67.83 Million USD | 59.827% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | -4.566% |
| Shattuck Labs, Inc. | -91.95 Million USD | 70.367% |
| CervoMed Inc. | -7.81 Million USD | -248.782% |
| Plus Therapeutics, Inc. | -13.32 Million USD | -104.564% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 43.434% |
| Moolec Science SA | -6.65 Million USD | -309.54% |
| Enveric Biosciences, Inc. | -16.44 Million USD | -65.669% |
| Design Therapeutics, Inc. | -78.19 Million USD | 65.149% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 68.693% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 32.714% |
| Achilles Therapeutics plc | -75.25 Million USD | 63.79% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -829.088% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 50.856% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 46.396% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 58.774% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 49.652% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 39.99% |
| Beam Therapeutics Inc. | -176.48 Million USD | 84.56% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 75.035% |
| AEON Biopharma, Inc. | -48.42 Million USD | 43.732% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 62.118% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 67.377% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | -116.495% |
| NeurAxis, Inc. | -6.66 Million USD | -308.883% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 94.083% |
| Lumos Pharma, Inc. | -36.61 Million USD | 25.575% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | 628.479% |
| Palisade Bio, Inc. | -13.07 Million USD | -108.493% |
| Nutriband Inc. | -4.87 Million USD | -459.327% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 62.382% |
| Neurogene Inc. | -55.58 Million USD | 50.974% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -220.551% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 71.823% |
| Athira Pharma, Inc. | -125.46 Million USD | 78.281% |
| HCW Biologics Inc. | -25.71 Million USD | -5.96% |
| XOMA Corporation | -41.84 Million USD | 34.883% |
| Nektar Therapeutics | -137.42 Million USD | 80.171% |
| Arvinas, Inc. | -401.5 Million USD | 93.213% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -308052.296% |
| Merus N.V. | -156.54 Million USD | 82.593% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 72.821% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 21.288% |
| Rezolute, Inc. | -70.42 Million USD | 61.305% |
| Clene Inc. | -40.54 Million USD | 32.782% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | -66.377% |
| BeyondSpring Inc. | -23.11 Million USD | -17.894% |
| Synlogic, Inc. | -55.16 Million USD | 50.599% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | -51.988% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -151.755% |
| Peak Bio, Inc. | -1356.23 USD | -2009146.219% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 32.721% |
| Krystal Biotech, Inc. | -109.72 Million USD | 75.166% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 78.964% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 92.056% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | -474.173% |
| MannKind Corporation | 8.67 Million USD | 414.012% |
| Ikena Oncology, Inc. | -75.41 Million USD | 63.868% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | -182.471% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 59.467% |
| Gossamer Bio, Inc. | -183.75 Million USD | 85.171% |
| CohBar, Inc. | -12.38 Million USD | -119.966% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 46.278% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 1.222% |
| Legend Biotech Corporation | -439.48 Million USD | 93.8% |
| Mural Oncology plc | -194.63 Million USD | 86.0% |
| Disc Medicine, Inc. | -91.12 Million USD | 70.096% |
| Champions Oncology, Inc. | -7.35 Million USD | -270.446% |
| REGENXBIO Inc. | -268.12 Million USD | 89.837% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -154.241% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 51.126% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 30.058% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 76.171% |
| Vaxart, Inc. | -83.34 Million USD | 67.305% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | -219.835% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 36.323% |
| Cellectis S.A. | -106.62 Million USD | 74.443% |
| Longeveron Inc. | -21.02 Million USD | -29.583% |
| Repare Therapeutics Inc. | -116.22 Million USD | 76.554% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 89.825% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 63.976% |
| Revolution Medicines, Inc. | -487.18 Million USD | 94.407% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | -309.651% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 38.003% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 63.467% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 60.867% |
| Anixa Biosciences, Inc. | -11.01 Million USD | -147.48% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 100.633% |
| Denali Therapeutics Inc. | -196.69 Million USD | 86.146% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -214.786% |
| Veru Inc. | -93.78 Million USD | 70.943% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | -16.807% |
| Cingulate Inc. | -22.75 Million USD | -19.732% |
| Passage Bio, Inc. | -108.38 Million USD | 74.859% |
| Context Therapeutics Inc. | -25.07 Million USD | -8.684% |
| Exicure, Inc. | -14.99 Million USD | -81.715% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 86.776% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 32.878% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | -180.438% |
| Nuvalent, Inc. | -149.49 Million USD | 81.772% |
| ABVC BioPharma, Inc. | -8.21 Million USD | -231.649% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 69.289% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | -31.174% |
| OmniAb, Inc. | -69.41 Million USD | 60.746% |
| Anew Medical, Inc. | -1.3 Million USD | -1994.8% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | -113.374% |
| Lipocine Inc. | -17.93 Million USD | -51.972% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 60.227% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 64.216% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 28.431% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 31.06% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | -21.739% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 95.301% |
| Ocugen, Inc. | -65.53 Million USD | 58.417% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 70.969% |
| Q32 Bio Inc. | -92.1 Million USD | 70.413% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | -27.105% |
| Alumis Inc. Common Stock | -158.17 Million USD | 82.772% |
| Equillium, Inc. | -14.52 Million USD | -87.646% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 56.334% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -244.791% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -44.447% |
| Dominari Holdings Inc. | -21.79 Million USD | -25.023% |
| Edesa Biotech, Inc. | -9.22 Million USD | -195.465% |
| vTv Therapeutics Inc. | -25.5 Million USD | -6.854% |
| Bio-Techne Corporation | 206.68 Million USD | 113.184% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 93.039% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 114.19% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 79.399% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 29.02% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 81.966% |
| Nkarta, Inc. | -131.65 Million USD | 79.301% |
| BioCardia, Inc. | -11.64 Million USD | -134.026% |
| Iterum Therapeutics plc | -47.46 Million USD | 42.593% |